Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105755 | 0.87 | PDE5A (0.34) | PDE5AP2RX3ADORA3PDE4APDE4B | |
| SCHEMBL24092237 | 0.87 | P2RX3 (0.35) | PDE5AP2RX3ADORA3PDE4APDE4B | |
| SCHEMBL22105361 | 0.85 | P2RX3 (0.32) | PDE5AP2RX3ADORA3PDE4APDE4B | |
| SCHEMBL22105423 | 0.83 | P2RX3 (0.35) | PDE5AP2RX3 | |
| SCHEMBL22105531 | 0.82 | ADORA3 (0.33) | PDE5AADORA3PDE4APDE4BPDE4C | |
| SCHEMBL22105716 | 0.82 | ADORA3 (0.33) | PDE5AADORA3PDE4APDE4BPDE4C | |
| SCHEMBL24092238 | 0.82 | P2RX3 (0.35) | P2RX3 | |
| SCHEMBL22105742 | 0.81 | P2RX3 (0.33) | PDE5AP2RX3 | |
| SCHEMBL22105553 | 0.80 | ADORA3 (0.40) | PDE5AADORA3PDE4APDE4BPDE4C | |
| SCHEMBL22105851 | 0.79 | ADORA3 (0.32) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | PDE5A 380/4885P2RX3 9/4885ADORA3 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.